AstraZeneca's Rare Miss: What This Means for the Pharma Powerhouse AstraZeneca, once a paragon of pharmaceutical excellence, has suffered a rare setback with the failure of its late stage clinical trial for Wainua, a heart disease drug.
The 9% drop in shares is significant, but it's the implicit loss of credibility that may have far reaching consequences.
Under CEO Pascal Soriot's leadership, AstraZeneca has built a reputation as a steadfast powerhouse, especially in oncology, over 14 years.